transplant renal.
Tratamentul rejetului de alogrefă rezistent la alte
terapii imunosupresoare, la pacienţii adulţi.
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA05 TACROLIMUSUM CAPS. ELIB. PREL 0,5 mg
ADVAGRAF 0,5 mg 0,5 mg ASTELLAS PHARMA GMBH
L04AA05 TACROLIMUSUM CAPS. 0.5 mg
PROGRAF(R) 0,5 mg 0.5 mg ASTELLAS PHARMA GMBH
L04AA05 TACROLIMUSUM CAPS. 1 mg
PROGRAF(R) 1 mg 1 mg ASTELLAS IRELAND CO. LTD.
L04AA05 TACROLIMUSUM CAPS. ELIB. PREL. 1 mg
ADVAGRAF 1 mg 1 mg ASTELLAS PHARMA GMBH
L04AA05 TACROLIMUSUM CAPS. 5 mg
PROGRAF(R) 5 mg 5 mg ASTELLAS PHARMA GMBH
L04AA05 TACROLIMUSUM CAPS. ELIB. PREL. 5 mg
ADVAGRAF 5 mg 5 mg ASTELLAS PHARMA GMBH
L04AA05 TACROLIMUSUM CONC. PT. SOL. PERF. 5 mg/ml
PROGRAF(R) 5 mg/ml 5 mg/ml ASTELLAS PHARMA GMBH
________________________________________________________________________________
______________________________________________________________________________
| 985 |L04AA06| MYCOPHENOLATUM** | |
|_______|_______|____________________________________________|_________________|
Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen renal.
Dostları ilə paylaş: | 
